

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

TechneScan PYP 20 mg kit for radiopharmaceutical preparation

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 20 mg sodium pyrophosphate decahydrate and 4 mg stannous chloride dihydrate (corresponding to 2.1 mg stannous).

The radionuclide is not part of the kit.

For a full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Kit for radiopharmaceutical preparation.

Powder for solution for injection.

Off-white to slightly yellow lyophilizate.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

This medicinal product is for diagnostic use only.

A. Red blood cell labelling for blood pool scintigraphy.

Major indications are:

- Angiocardiography for:
  - \* evaluation of ventricular ejection fraction
  - \* evaluation of global and regional cardiac wall motion
  - \* myocardial phase imaging
- Organ perfusion and vascular abnormalities imaging for the detection of hemangioma.
- Diagnosis and localization of occult gastro-intestinal bleeding

B. Determination of blood volume

C. Spleen scintigraphy

#### 4.2 Posology and method of administration

##### Posology

##### Adults

A. Blood pool scintigraphy:

The average activity administered after intravenous injection for *in vivo* or after *in vitro* labelling is 890 MBq (740-925 MBq).

B. Determination of blood volume:

The average activity administered after intravenous injection after *in vitro* labelling is 3 MBq (1-5 MBq).

C. Spleen scintigraphy:

The average activity administered after intravenous injection after *in vitro* labelling of denatured erythrocytes is 50 MBq (20-70 MBq).

The optimal amount of nonradioactive stannous tin for preparation of red blood cells (RBCs) *in vivo* or *in vitro* is 10 to 20 µg/kg body weight in adults. Especially in cases of *in vitro* labelling this dose should not be exceeded. Sodium pertechnetate (<sup>99m</sup>Tc) should be injected (*in vivo*) or added to the incubation mixture (*in vitro*) after 30 minutes.

#### Renal impairment

Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.

#### Paediatric population

The use in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group.

The activities to be administered to children and to adolescents may be calculated according to the EANM dosage card version 2016 for the indication:

Blood pool scintigraphy.

$A[MBq]_{Administered} = 56.0 \times \text{Multiple from table 1}$

Spleen scintigraphy:

$A[MBq]_{Administered} = 2.8 \times \text{Multiple from table 1}$

Table 1

3 kg = 1	22 kg = 5.29	42 kg = 9.14
4 kg = 1.14	24 kg = 5.71	44 kg = 9.57
6 kg = 1.71	26 kg = 6.14	46 kg = 10.00
8 kg = 2.14	28 kg = 6.43	48 kg = 10.29
10 kg = 2.71	30 kg = 6.86	50 kg = 10.71
12 kg = 3.14	32 kg = 7.29	52-54 kg = 11.29
14 kg = 3.57	34 kg = 7.72	56-58 kg = 12.00
16 kg = 4.00	36 kg = 8.00	60-62 kg = 12.71
18 kg = 4.43	38 kg = 8.43	64-66 kg = 13.43
20 kg = 4.86	40 kg = 8.86	68 kg = 14.00

For blood scintigraphy, in very young infants (up to 1 year) a minimum dose of 80 MBq is necessary in order to obtain images of sufficient quality. For spleen scintigraphy a minimum dose of 20 MBq is necessary.

#### Method of administration

Multidose vial.

For intravenous injection.

This medicinal product should be reconstituted before administration to the patient. For instructions regarding reconstitution, see section 12.

For patient preparation, see section 4.4.

The freeze-dried stannous pyrophosphate lyophilizate (non-radioactive substance) is first reconstituted with isotonic sodium chloride solution for injection.

#### *In vivo RBCs labelling method:*

Injection of the reconstituted solution of the stannous pyrophosphate complex followed by injection of sodium pertechnetate (<sup>99m</sup>Tc) 30 minutes later.

#### *In vitro RBCs labelling method:*

- Sampling of 6 ml of the patient's blood
- *In vitro* incubation of the reconstituted solution of the taken total blood sample or separated RBCs, followed by adding sodium pertechnetate (<sup>99m</sup>Tc) 30 minutes later.

- *Second in vitro* incubation of the RBCs and reinjection of the labelled RBCs 30 minutes later.

*Modified in vivo RBCs labelling method (in vivo/in vitro):*

- Injection of the reconstituted solution of the stannous pyrophosphate for *in vivo* “stannous-loading” of RBCs.
- *In vitro* RBCs labeling with sodium pertechnetate ( $^{99m}\text{Tc}$ ) after taking a blood sample.
- Reinjection of the labelled RBCs.

*Denatured RBCs labelling method:*

- *In vitro* labelling of RBCs (see above) followed by denaturation e.g. heating of the labelled erythrocytes at 49-50°C for 25 minutes.
- Reinjection of the labelled denatured RBCs.

## Image acquisition

### Angiocardiography:

The acquisition of images starts immediately after the injection of the tracer.

### Occult digestive haemorrhages:

Since digestive bleeding occurs usually intermittently, it is recommended to perform several acquisitions over a period of 24 hours in addition to the images acquired initially after the injection.

### Spleen scintigraphy:

Images are performed from 30 to 120 minutes after the injection. In case of accessory spleen research, the entire abdomen should be studied. If the patient has diaphragm rupture due to previous trauma, the chest should also be studied.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Potential for hypersensitivity or anaphylactic reactions

If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately, and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available.

### Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.

### Renal impairment

Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.

### Paediatric population

For information on the use in paediatric population, see section 4.2.

Careful consideration of the indication is required since the effective dose per MBq is higher than in adults, see section 11.

### After the procedure

Close contact with infants and pregnant women should be restricted during 2 hours after administration of the labelled RBCs or sodium pertechnetate ( $^{99m}\text{Tc}$ ).

### Specific warnings

### Scintigraphy repeatability

Because of the long-lasting fixation of stannous salts on red blood cells, it is recommended not to repeat the procedure before 3 months.

#### Interaction with iodinated contrast media

It is recommended to perform the scintigraphy with ( $^{99m}\text{Tc}$ )-labelled red blood cells in advance of any administration of the iodinated contrast media, otherwise the efficiency of the red blood cell labelling will be adversely affected (see section 4.5).

#### Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'. Depending on the time when you administer the injection, the content of sodium given to the patient may in some cases be greater than 1 mmol. This should be taken into account in patient on low sodium diet.

Precautions with respect to environmental hazard see section 6.6.

### **4.5 Interaction with other medicinal products and other forms of interaction**

Reduction in red blood cell labelling yield has been reported with heparin, tin overload, aluminium, prazosin, methyl dopa, hydralazine, digitalic related compounds, quinidine,  $\beta$ -adrenergic blockers (e.g. propranolol), calcium channel blockers (e.g. verapamil, nifedipine), nitrates (e.g. nitroglycerine), anthracycline antibiotic, iodinated contrast agents and teflon catheter (the  $\text{Sn}^{++}$  can react with the catheter).

### **4.6 Fertility, pregnancy and lactation**

#### Women of childbearing potential

When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. If in doubt about her potential pregnancy (if the woman has missed a period, if a period is very irregular, etc), alternative techniques not using ionising radiation (if there are any) should be offered to the patient.

#### Pregnancy

Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. Only essential investigations should therefore be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus.

Administration of 925 MBq results in an absorbed dose to the uterus of 3.6 mGy.

#### Breast-feeding

Before administering radiopharmaceuticals to a mother who is breast-feeding, a consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk.

Sodium pertechnetate ( $^{99m}\text{Tc}$ ) is excreted in human milk. If the administration is considered necessary and depending on the RBCs labelling method, breastfeeding should at least be interrupted for about 12 hours after the sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection (*in vivo* labelling method) or for about 4 hours after the reinjection of the labelled RBCs (other labelling methods), and the expressed feeds discarded.

Close contact with infants should be restricted during 2 hours (see section 4.4).

#### Fertility

There are no data on possible harmful effects of TechneScan PYP on fertility.

### **4.7 Effects on ability to drive and use machines**

TechneScan PYP has no or negligible influence on the ability to drive and use machines.

#### 4.8 Undesirable effects

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 6.5 mSv when the maximal recommended activity of 925 MBq is administered, these adverse reactions are expected to occur with a low probability.

Information on adverse reactions is available from spontaneous reporting. The reports describe anaphylactoid, vasovagal and injection site reactions.

Adverse Reactions sorted by System Organ Class:

<b>Immune system disorders</b> Frequency not known*	Anaphylactoid reaction [e.g. general skin pruritus, vasodilation, urticaria, erythema, diaphoresis, facial oedema, swollen arm, nausea, vomiting, flushing, cardiac arrhythmias (tachycardia), hypotension, hyperhidrosis, coma, dyspnoea, dysphagia, muscle spasms, lacrimation increased, myalgia, taste disorder].
<b>Nervous system disorders</b> Frequency not known*	Vasovagal reaction (e.g. syncope, headache, dizziness, confusional state, bradycardia, tinnitus, tremor, chills, pallor, blurred vision, paraesthesia).
<b>General disorders and administration site conditions</b> Frequency not known*	Chest pain. Injection site reactions (e.g. skin rash, pruritus, cellulitis, inflammation, pain, swelling)

\* Frequency cannot be estimated from the available data.

##### Anaphylactoid reactions

Reported anaphylactoid reactions were mild to moderate, however the occurrence of severe reactions cannot be excluded. If anaphylactoid reactions occur, the medicinal product must no longer be administered. Appropriate instruments (including endotracheal tube and ventilator) and medications should be to hand to be able to react immediately in an emergency.

##### Vasovagal reactions

Vasovagal reactions are most probably caused by the procedure itself, especially in anxious patients, but a contribution of the product cannot be excluded.

##### Injection site reactions

Local reactions at the injection site may include rashes, pruritus, cellulitis, swelling, inflammation and pain. In most cases such reactions are probably caused by extravasation. Extended extravasation may necessitate surgical treatment.

##### Paediatric population

It must be taken into account that the effective dose per MBq is higher than in adults (see section 11. "Dosimetry").

##### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

## 4.9 Overdose

In the event of an administered radiation overdose on Technescan PYP, very little can be done since the elimination of it completely depends of the regular hemolytic process.

Forced diuresis and frequent bladder voiding are recommended in the case of overdosage with sodium pertechnetate ( $^{99m}\text{Tc}$ ).

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Diagnostic radiopharmaceuticals for cardiovascular system, Technetium ( $^{99m}\text{Tc}$ ) compounds.

ATC code: V09GA06.

At doses used for diagnostic procedures, neither stannous pyrophosphate, sodium pertechnetate ( $^{99m}\text{Tc}$ ) nor stannous pyrophosphate ( $^{99m}\text{Tc}$ ), nor labelled Red Blood Cells appear to have any pharmacodynamic effect.

### 5.2 Pharmacokinetic properties

#### Distribution

Intravenous injection of stannous salts induces a “stannous loading” of erythrocytes. Subsequent sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection results in an accumulation and a retention of sodium pertechnetate ( $^{99m}\text{Tc}$ ) in the choroid plexus and red blood cells.

Intravenous administration of 10-20  $\mu\text{g}$  stannous ion/kg body weight (in form of stannous pyrophosphate) followed 30 minutes later by 370-740 MBq pertechnetate injection results in efficient labelling of blood pool.

#### Organ uptake

Under normal circumstances intravenously injected pertechnetate freely diffuses into and out from the erythrocytes. However, when the erythrocytes have been preloaded with stannous ion, the sodium pertechnetate ( $^{99m}\text{Tc}$ ) is reduced within the cells and becomes bound to the chains of globin. The mechanisms by which sodium pertechnetate ( $^{99m}\text{Tc}$ ) becomes attached to tin primed red blood cells are not clearly understood. However, 20 % of injected pertechnetate enters the red cell and binds to a beta chain of globin, while the remaining 70-80 % of pertechnetate is believed to be located in the cytoplasm or on the red cell membrane. On the other hand reducing the surface charge of the erythrocytes decreases the efficiency of labelling down to 20 %.

#### Elimination

The most beneficial time for the injection of ( $^{99m}\text{Tc}$ ) pertechnetate for the *in vivo* labelling is 20-30 min after the administration of pyrophosphate. At 10 and 100 minutes post injection,  $77 \pm 15 \%$  and  $71 \pm 14 \%$  respectively, of the injected activity is found in the blood. This value remains constant for about 2 hours after injection with only about 6 % decrease in total blood radioactivity during this period.

#### Half-life

Up to eight days after the examination, labelling of erythrocytes with ( $^{99m}\text{Tc}$ ) pertechnetate may still be observed. There is no appreciable effect with doses of up to 0.02 mg of tin/kg. The heat-denatured erythrocytes are sequestered by splenic pulp.

Technetium-99m ( $^{99m}\text{Tc}$ ) has a physical half-life of 6 hours.

### **5.3 Preclinical safety data**

There are no preclinical safety data specific to technetium labelled erythrocytes. The toxicity of pertechnetate ion and stannous salts has been studied and reported in the literature. Systemic toxic effects are only observed at relatively high parenteral doses, giving a safety ratio of at least 150. Repeated dose toxicity studies in rats with 50-100 times human dose do not cause macroscopic nor microscopic alterations. Stannous salts are reported to have a weak potential for mutagenicity. There are no studies describing possible effects on reproduction or tumour incidence.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Stannous chloride dihydrate  
Hydrochloric acid  
Sodium hydroxide (for pH-adjustment )

### **6.2 Incompatibilities**

This medicinal product must not be mixed with other medicinal products except those mentioned in section 12.

### **6.3 Shelf life**

1 year.

After reconstitution: 4 hours. After reconstitution, store in a refrigerator (2-8 °C).

From microbiological point of view the product should be used immediately.

### **6.4 Special precautions for storage**

Store in a refrigerator (2-8 °C).

For storage conditions after reconstitution of the medicinal product, see section 6.3.

Storage should be in accordance with national regulations for radioactive material.

### **6.5 Nature and contents of container**

10 ml glass vial (type 1 Ph. Eur.) closed with a bromobutyl stopper, sealed with an aluminium cap.

Pack size: five vials in a carton.

### **6.6 Special precautions for disposal and other handling**

#### General warnings

Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of the local competent authorities.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiological safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

Contents of the vial are intended only for use in the preparation of radiopharmaceuticals and are not to be administered directly to the patient without first undergoing the reconstitution procedure.

For instructions on reconstitution of the medicinal product before administration, see section 12.

If at any time in the preparation of this product the integrity of this vial is compromised, it should not be used.

Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The content of the kit is not radioactive. However, after sodium pertechnetate ( $^{99m}\text{Tc}$ ) is added to the RBCs during *in vitro* RBC labelling, adequate shielding of the final preparation must be maintained.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting etc. Radiation protection precautions in accordance with national regulations must therefore be taken.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. PRODUCT OWNER**

### Manufactured and released by:

Curium Netherlands B.V.  
Westerduinweg 3  
1755 LE PETTEN  
The Netherlands

### Marketing Authorisation Holder:

QT Instruments (S) Pte Ltd  
100H Pasir Panjang Road  
#07-01 OC@Pasir Panjang  
Singapore 118524

## **8. MARKETING AUTHORISATION NUMBER(S)**

SIN16274P

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

09.07.2021

## **10. DATE OF REVISION OF THE TEXT**

08.05.2023

## **11. DOSIMETRY**

Technetium ( $^{99m}\text{Tc}$ ) is produced by means of a ( $^{99}\text{Mo}/^{99m}\text{Tc}$ ) generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium ( $^{99m}\text{Tc}$ ) which, in view of its long half-life of  $2.13 \times 10^5$  years can be regarded as quasi stable.

The radiation doses absorbed by a patient with a body weight of 70 kg after intravenous injection of  $^{99m}\text{Tc}$ -labelled erythrocytes according to ICRP 128 (2015) and  $^{99m}\text{Tc}$ -labelled denatured erythrocytes according to ICRP 53 (1988), are as following.



**<sup>99m</sup>Tc-LABELLED ERYTHROCYTES**

<b>Organ</b>	<b>Absorbed dose per unit activity administered (mGy/MBq)</b>				
	<b>Adult</b>	<b>15 Years</b>	<b>10 years</b>	<b>5 years</b>	<b>1 year</b>
Adrenals	0.0099	0.012	0.02	0.03	0.056
Bone Surfaces	0.0074	0.012	0.019	0.036	0.074
Brain	0.0036	0.0046	0.0075	0.012	0.022
Breast	0.0035	0.0041	0.007	0.011	0.019
Gall bladder wall	0.0065	0.0081	0.013	0.02	0.03
GI-tract					
Stomach wall	0.0046	0.0059	0.0097	0.014	0.025
Small Intestine wall	0.0039	0.0049	0.0078	0.012	0.021
Colon wall	0.0037	0.0048	0.0075	0.012	0.02
ULI wall	0.004	0.0051	0.008	0.013	0.022
LLI wall	0.0034	0.0044	0.0069	0.01	0.018
Heart wall	0.023	0.029	0.043	0.066	0.11
Kidneys	0.018	0.022	0.036	0.057	0.11
Liver	0.013	0.017	0.026	0.04	0.072
Lungs	0.018	0.022	0.035	0.056	0.11
Muscles	0.0033	0.004	0.0061	0.0094	0.017
Oesophagus	0.0061	0.007	0.0098	0.015	0.023
Ovaries	0.0037	0.0048	0.007	0.011	0.019
Pancreas	0.0066	0.0081	0.013	0.019	0.033
Red marrow	0.0061	0.0076	0.012	0.02	0.037
Skin	0.002	0.0024	0.0038	0.0062	0.012
Spleen	0.014	0.017	0.027	0.043	0.081
Testes	0.0023	0.003	0.0044	0.0069	0.013
Thymus	0.0061	0.007	0.0098	0.015	0.023
Thyroid	0.0057	0.0071	0.012	0.019	0.036
Urinary bladder wall	0.0085	0.011	0.014	0.017	0.031
Uterus	0.0039	0.0049	0.0074	0.011	0.019
Remaining organs	0.0035	0.0045	0.0073	0.013	0.023
<b>Effective dose (mSv/MBq)</b>	<b>0.007</b>	<b>0.0089</b>	<b>0.014</b>	<b>0.021</b>	<b>0.039</b>

For blood pool scintigraphy the effective dose resulting from the administration of a (maximum recommended) activity of 925 MBq is 6.5 mSv (for an adult weighing 70 kg) and the typical radiation dose to the critical organ (heart) is 21.3 mGy.

For blood volume determination the effective dose resulting from the administration of a (maximal recommended) activity of 5 MBq is 0.035 mSv (for an adult weighing 70 kg) and the typical radiation dose to the critical organ (heart) is 0.12 mGy.

**<sup>99m</sup>Tc-LABELLED DENATURED ERYTHROCYTES**  
Absorbed dose per unit activity administered (mGy/MBq)

	<b>Adult</b>	<b>15 Years</b>	<b>10 years</b>	<b>5 years</b>	<b>1 year</b>
Adrenals	0.013	0.018	0.027	0.038	0.063
Bladder wall	0.00075	0.0011	0.0021	0.0038	0.0073
Bone Surfaces	0.0031	0.0041	0.0061	0.0095	0.019
Breast	0.0021	0.0021	0.0041	0.0068	0.010
GI-tract					
Stomach wall	0.019	0.021	0.030	0.040	0.058
Small intestine	0.0037	0.0046	0.0077	0.013	0.022
ULI wall	0.0040	0.0049	0.0085	0.014	0.023
LLI wall	0.0017	0.0023	0.0043	0.0069	0.013
Heart	0.0060	0.0073	0.011	0.016	0.026
Kidneys	0.018	0.022	0.032	0.046	0.070
Liver	0.018	0.023	0.034	0.049	0.087
Lungs	0.0057	0.0075	0.011	0.017	0.028
Ovaries	0.0014	0.0022	0.0039	0.0070	0.012
Pancreas	0.036	0.040	0.057	0.078	0.12
Red marrow	0.0043	0.0060	0.0084	0.011	0.017
Spleen	0.56	0.78	1.2	1.8	3.2
Testes	0.00047	0.00059	0.0011	0.0017	0.0041
Thyroid	0.00063	0.0010	0.0018	0.0032	0.0066
Uterus	0.0014	0.0018	0.0036	0.0059	0.011
Other tissue	0.0033	0.0041	0.0058	0.0087	0.015
<b>Effective dose * (mSv/MBq)</b>	<b>0.019</b>	<b>0.026</b>	<b>0.04</b>	<b>0.06</b>	<b>0.1</b>

\* Calculation according to ICRP 60

For spleen scintigraphy the effective dose resulting from the administration of a (maximum recommended) activity of 70 MBq is 1.3 mSv (for an adult weighing 70 kg) and the typical radiation dose to the critical organ (spleen) is 39.2 mGy.

## 12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Withdrawals should be performed under aseptic conditions. The vials must never be opened before disinfecting the stopper, the solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system.

If the integrity of this vial is compromised, the product should not be used.

The freeze-dried stannous pyrophosphate lyophilizate (non-radioactive substance) is first reconstituted with isotonic sodium chloride solution. TechneScan PYP is a colourless solution after reconstitution. Reconstituted solution is then used for *in vivo*, *in vitro* or *in vivo/in vitro* labelling of red blood cells by different methods.

### In vivo RBCs labelling

#### Blood pool scintigraphy:

- In the case of ca. 70 kg body weight: slowly inject (10-20 seconds) 1/3 of the whole contents of one vial TechneScan PYP dissolved in 6 ml of an isotonic sodium chloride solution (2 ml for 70 kg). The volume should be adapted for other body weights
- Inject approximately 30 minutes later 740-925 MBq pertechnetate ( $^{99m}\text{Tc}$ ) intravenously

### In vitro RBCs labelling

- Collect 6 ml blood from the patient in ACD (acid citrate dextrose)
- Remove plasma by centrifugation and perform a wash step with isotonic sodium chloride
- Resuspend the erythrocytes in ca 10 ml isotonic sodium chloride solution
- Dissolve a vial TechneScan PYP in 6 ml isotonic sodium chloride solution
- Add 0.3 ml (105  $\mu\text{g}$  Sn) reconstituted solution to the erythrocyte suspension
- Incubate for 30 minutes at room temperature
- Remove excess  $\text{Sn}^{2+}$  by centrifugation and by resuspension of the cells in 5 ml sodium chloride
- Repeat this wash step
- Add 740-925 MBq  $^{99m}\text{TcO}_4^-$
- Incubate 30 minutes at room temperature
- Remove unbound  $^{99m}\text{Tc}$  by centrifugation
- Determine the labelling yield; this should be  $>85\%$
- Reinject the labelled RBCs in the patient

### In vivo/in vitro RBCs labelling

- TechneScan PYP is reconstituted with 6 ml sterile, non-pyrogenic isotonic sodium chloride solution. One third of the vial is administered to the patient.
- 30 minutes later, collect 6 ml blood from the patient in ACD tubes. Add sodium pertechnetate ( $^{99m}\text{Tc}$ ) and incubate 30 minutes at room temperature.
- Remove plasma and unbound pertechnetate by centrifugation and perform a wash step with 5 ml isotonic sodium chloride.
- Repeat this centrifugation and wash step.
- Reinject the labelled RBCs in the patient.

### Denatured RBCs labelling method

- *In vitro* labelling of RBCs (see above) followed by denaturation e.g. heating of the labelled erythrocytes at 49-50°C for 25 minutes
- Reinject the labelled denatured RBCs in the patient.